Efficacy and safety of adalimumab in crohn's disease: Meta-analysis of placebo-controlled trials

Journal of Digestive Diseases

Volumn 12, Issue 3, 2011, Pages 165-172

  Huang, Mei Lan ^a   Ran, Zhi Hua ^a   Shen, Jun ^a   Li, Xiao Bo ^a   Xu, Xi Tao ^a   Xiao, Shu Dong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Adalimumab; Crohn's disease; Meta analysis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; PLACEBO;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; CROHN DISEASE; DRUG EFFICACY; DRUG SAFETY; FATIGUE; HEADACHE; HUMAN; INFECTION; LARYNX PAIN; META ANALYSIS; NAUSEA; NEOPLASM; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RHINOPHARYNGITIS; SYSTEMATIC REVIEW;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; C-REACTIVE PROTEIN; CONTROLLED CLINICAL TRIALS AS TOPIC; CROHN DISEASE; HUMANS; PLACEBOS; TREATMENT OUTCOME;

EID: 79957585339     PISSN: 17512972     EISSN: 17512980     Source Type: Journal    
DOI: 10.1111/j.1751-2980.2011.00493.x     Document Type: Article

References (25)

1. Ahuja V, Tandon RK. Inflammatory bowel disease in the Asia-Pacific area: a comparison with developed countries and regional differences. J Dig Dis 2010; 11: 134-47.
2. Feller M, Huwiler K, Schoepfer A, Shang A, Furrer H, Egger M. Long-term antibiotic treatment for Crohn's disease: systematic review and meta-analysis of placebo-controlled trials. Clin Infect Dis 2010; 50: 473-80.
3. Rahimi R, Nikfar S, Rahimi F etal. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 2008; 53: 2524-31.
4. Cosnes J, Nion-Larmurier I, Beaugerie L, Afchain P, Tiret E, Gendre JP. Impact of the increasing use of immunosuppressants in Crohn's disease on the need for intestinal surgery. Gut 2005; 54: 237-41.
5. D'Haens G. Anti-TNF treatment in Crohn's disease: toward tailored therapy? Am J Gastroenterol 2010; 105: 1140-1.
6. Burmester GR, Mease P, Dijkmans BA etal. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. Ann Rheum Dis 2009; 68: 1863-9.
7. Behm BW, Bickston SJ. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2008; (1): CD006893.
8. Peyrin-Biroulet L, Deltenre P, de Suray N, Branche J, Sandborn WJ, Colombel JF. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol 2008; 6: 644-53.
9. Loftus EV, Rubin DT, Chen NJ, Mulani P, Chao JD. Remission and quality-of-life improvements sustained with adalimumab in anti-TNF-naïve patients with Crohn's disease: 3-year data from CHARM. Gastroenterology 2009; 136: A180.
10. Colombel JF, Sandborn WJ, Rutgeerts P etal. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol 2009; 104: 1170-9.
11. Feagan BG, Panaccione R, Sandborn WJ etal. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology 2008; 135: 1493-9.
12. Panaccione R, Colombel JF, Sandborn WJ etal. Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease. Aliment Pharmacol Ther 2010; 31: 1296-309.
13. Jadad AR, Moore RA, Carroll D etal. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996; 17: 1-12.
14. Moher D, Pham B, Jones A etal. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998; 352: 609-13.
15. Sandborn WJ, Rutgeerts P, Enns R etal. Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med 2007; 146: 829-38.
16. Hanauer SB, Sandborn WJ, Rutgeerts P etal. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology 2006; 130: 323-33.
17. Colombel JF, Sandborn WJ, Rutgeerts P etal. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology 2007; 132: 52-65.
18. Sandborn WJ, Hanauer SB, Rutgeerts P etal. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut 2007; 56: 1232-9.
19. Casellas F, Lopez-Vivancos J, Badia X, Vilaseca J, Malagelada JR. Influence of inflammatory bowel disease on different dimensions of quality of life. Eur J Gastroenterol Hepatol 2001; 13: 567-72.
20. Irvine EJ, Feagan B, Rochon J etal. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Gastroenterology 1994; 106: 287-96.
21. Jarnerot G, Hertervig E, Friis-Liby I etal. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128: 1805-11.
22. Hanauer SB, Feagan BG, Lichtenstein GR etal. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
23. Colombel JF, Sandborn WJ, Reinisch W etal. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362: 1383-95.
24. Schwartz D, Colombel JF, Rutgeerts P etal. Sustained improvement in quality of life for patients with fistulizing Crohn's disease treated with adalimumab: 3-year data from CHARM. Gastroenterology 2009; 136: A180-A181.
25. Ho GT, Smith L, Aitken S etal. The use of adalimumab in the management of refractory Crohn's disease. Aliment Pharmacol Ther 2008; 27: 308-15.